Analysts Expect La Jolla Pharmaceutical (NASDAQ:LJPC) to Post -$1.07 EPS

Wall Street brokerages predict that La Jolla Pharmaceutical (NASDAQ:LJPC) will announce earnings per share (EPS) of ($1.07) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for La Jolla Pharmaceutical’s earnings, with estimates ranging from ($1.09) to ($1.03). La Jolla Pharmaceutical reported earnings per share of ($1.93) during the same quarter last year, which would suggest a positive year over year growth rate of 44.6%. The firm is scheduled to report its next quarterly earnings results on Wednesday, October 23rd.

According to Zacks, analysts expect that La Jolla Pharmaceutical will report full year earnings of ($4.39) per share for the current financial year, with EPS estimates ranging from ($4.50) to ($4.23). For the next financial year, analysts forecast that the business will report earnings of ($2.94) per share, with EPS estimates ranging from ($3.46) to ($2.53). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow La Jolla Pharmaceutical.

La Jolla Pharmaceutical (NASDAQ:LJPC) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($1.12). La Jolla Pharmaceutical had a negative return on equity of 715.12% and a negative net margin of 891.53%. The company had revenue of $5.70 million during the quarter, compared to analysts’ expectations of $5.76 million.

LJPC has been the topic of several recent analyst reports. BidaskClub lowered La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, September 27th. Chardan Capital reaffirmed a “buy” rating on shares of La Jolla Pharmaceutical in a research note on Thursday, August 15th. ValuEngine raised La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. HC Wainwright set a $27.00 price target on La Jolla Pharmaceutical and gave the company a “buy” rating in a research note on Thursday, August 29th. Finally, Zacks Investment Research lowered La Jolla Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Thursday, August 8th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $15.50.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC lifted its stake in La Jolla Pharmaceutical by 3.3% during the 1st quarter. FMR LLC now owns 4,061,425 shares of the biopharmaceutical company’s stock worth $26,115,000 after acquiring an additional 128,074 shares in the last quarter. Sio Capital Management LLC acquired a new position in La Jolla Pharmaceutical during the 2nd quarter worth about $12,121,000. VHCP Management III LLC lifted its stake in La Jolla Pharmaceutical by 24.7% during the 2nd quarter. VHCP Management III LLC now owns 1,251,898 shares of the biopharmaceutical company’s stock worth $11,580,000 after acquiring an additional 248,298 shares in the last quarter. Vanguard Group Inc. lifted its stake in La Jolla Pharmaceutical by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 1,045,292 shares of the biopharmaceutical company’s stock worth $9,669,000 after acquiring an additional 12,097 shares in the last quarter. Finally, Boxer Capital LLC acquired a new position in La Jolla Pharmaceutical during the 2nd quarter worth about $5,319,000.

Shares of La Jolla Pharmaceutical stock traded up $0.09 during trading hours on Monday, hitting $8.54. The company’s stock had a trading volume of 5,566 shares, compared to its average volume of 289,319. La Jolla Pharmaceutical has a twelve month low of $5.01 and a twelve month high of $18.04. The firm has a fifty day moving average of $9.47 and a 200-day moving average of $8.53. The stock has a market cap of $231.78 million, a price-to-earnings ratio of -1.09 and a beta of 2.14.

La Jolla Pharmaceutical Company Profile

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.

Read More: Understanding Market Liquidity

Get a free copy of the Zacks research report on La Jolla Pharmaceutical (LJPC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.